[go: up one dir, main page]

PE20091032A1 - Composicion que contiene n-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridin-3-sulfonamida (zibotentan) - Google Patents

Composicion que contiene n-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridin-3-sulfonamida (zibotentan)

Info

Publication number
PE20091032A1
PE20091032A1 PE2008001750A PE2008001750A PE20091032A1 PE 20091032 A1 PE20091032 A1 PE 20091032A1 PE 2008001750 A PE2008001750 A PE 2008001750A PE 2008001750 A PE2008001750 A PE 2008001750A PE 20091032 A1 PE20091032 A1 PE 20091032A1
Authority
PE
Peru
Prior art keywords
zibotentan
methylpyrazin
oxadiazol
sulfonamide
pyridin
Prior art date
Application number
PE2008001750A
Other languages
English (en)
Inventor
John David Blyth
Andrew John Day
Kieran James Lennon
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40534840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091032(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20091032A1 publication Critical patent/PE20091032A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA QUE CONTIENE N-(3-METOXI-5-METILPIRAZIN-2-IL)-2-(4-[1,3,4-OXADIAZOL-2-IL]FENIL)PIRIDIN-3-SULFONAMIDA (I) (ZIBOTENTAN) EN UNA CANTIDAD DE 2 A 20% EN PESO, MANITOL EN UNA CANTIDAD DE 65% A 75% EN PESO Y/O CELULOSA MICROCRISTALINA EN UNA CANTIDAD DE 10% A 15% EN PESO. TAMBIEN CONTIENE UNO O MAS AGLUTINANTES TAL COMO POVIDONA, UNO O MAS DESINTEGRANTES TAL COMO CROSCAMELOSA SODICA. EL COMPUESTO ZIBOTENTAN ES UN ANTAGONISTA DE LA ENDOTELINA Y ES UTIL EN EL TRATAMIENTO DEL CANCER
PE2008001750A 2007-10-12 2008-10-10 Composicion que contiene n-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridin-3-sulfonamida (zibotentan) PE20091032A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97973607P 2007-10-12 2007-10-12
US8911808P 2008-08-15 2008-08-15

Publications (1)

Publication Number Publication Date
PE20091032A1 true PE20091032A1 (es) 2009-08-15

Family

ID=40534840

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001750A PE20091032A1 (es) 2007-10-12 2008-10-10 Composicion que contiene n-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridin-3-sulfonamida (zibotentan)

Country Status (35)

Country Link
US (2) US8168221B2 (es)
EP (2) EP2433620A1 (es)
JP (1) JP2011500548A (es)
KR (1) KR20100099113A (es)
CN (1) CN101896210A (es)
AR (1) AR068845A1 (es)
AT (1) ATE536893T1 (es)
AU (1) AU2008309385B2 (es)
BR (1) BRPI0818323A2 (es)
CA (1) CA2701385A1 (es)
CL (1) CL2008003022A1 (es)
CO (1) CO6270344A2 (es)
CR (1) CR11363A (es)
CU (1) CU20100064A7 (es)
CY (1) CY1112433T1 (es)
DK (1) DK2209501T3 (es)
DO (1) DOP2010000105A (es)
EA (1) EA201000545A1 (es)
ES (1) ES2377426T3 (es)
HK (1) HK1143095A1 (es)
HR (1) HRP20120085T1 (es)
IL (1) IL204953A0 (es)
MX (1) MX2010003989A (es)
NI (1) NI201000052A (es)
NZ (1) NZ585310A (es)
PE (1) PE20091032A1 (es)
PL (1) PL2209501T3 (es)
PT (1) PT2209501E (es)
SG (1) SG182138A1 (es)
SI (1) SI2209501T1 (es)
SV (1) SV2010003529A (es)
TW (1) TW200924768A (es)
UY (1) UY31385A1 (es)
WO (1) WO2009047565A2 (es)
ZA (1) ZA201002477B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1816527A (zh) 2003-06-06 2006-08-09 菲布罗根有限公司 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
WO2009047565A2 (en) 2007-10-12 2009-04-16 Astrazeneca Ab Composition 064
CN101822796B (zh) * 2010-03-17 2012-01-04 山西仟源制药有限公司 一种银冰含片及制备方法和应用
US9492395B2 (en) * 2010-05-11 2016-11-15 Sensient Colors Llc Film coating composition and methods of making and using the same
JO3753B1 (ar) * 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
MX369549B (es) * 2012-04-27 2019-11-12 Merck Patent Gmbh Un proceso para la fabricación de núcleos de tabletas duros con recubrimiento.
LT3470397T (lt) 2012-07-16 2022-02-25 Fibrogen, Inc. Prolilo hidroksilazės inhibitoriaus kristalinės formos
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
SMT202000190T1 (it) 2013-06-06 2020-05-08 Fibrogen Inc Formulazioni farmaceutiche di un inibitore di hif-idrossilasi
TW202203971A (zh) * 2020-03-31 2022-02-01 日商衛材R&D企管股份有限公司 錠劑、醫藥及其等之製造方法以及套組

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674794A (en) * 1970-03-18 1972-07-04 Ciba Geigy Corp Certain-3-pyridine-sulfonamide derivatives
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
CN1179961C (zh) * 1997-04-28 2004-12-15 安瑟希夫制药公司 用于治疗内皮肽介导之疾病的磺酰胺
US5783705A (en) * 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
JP2001058944A (ja) * 1999-06-18 2001-03-06 Takeda Chem Ind Ltd 速崩壊性固形製剤
CA2374760A1 (en) * 1999-06-18 2000-12-28 Takeda Chemical Industries, Ltd. Quickly disintegrating solid preparations
CN1615135A (zh) 2001-11-13 2005-05-11 法马西亚公司 磺酰胺前药如帕瑞考昔的口服剂型
GB0219660D0 (en) * 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
WO2004026233A2 (en) * 2002-09-20 2004-04-01 Merck & Co., Inc. Mannitol formulation for integrin receptor antagonist
GB0223854D0 (en) 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
GB0320806D0 (en) 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
US7772232B2 (en) 2004-04-15 2010-08-10 Bristol-Myers Squibb Company Quinazolinyl compounds as inhibitors of potassium channel function
GB0425854D0 (en) 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
CN101032464A (zh) * 2007-04-01 2007-09-12 杨喜鸿 含有利莫那班和聚乙烯吡咯烷酮的组合物、固体分散体及其制备和药物应用
WO2009047565A2 (en) 2007-10-12 2009-04-16 Astrazeneca Ab Composition 064

Also Published As

Publication number Publication date
SI2209501T1 (sl) 2012-03-30
CU20100064A7 (es) 2011-10-05
DK2209501T3 (da) 2012-02-27
AR068845A1 (es) 2009-12-09
ZA201002477B (en) 2010-12-29
EP2433620A1 (en) 2012-03-28
KR20100099113A (ko) 2010-09-10
IL204953A0 (en) 2010-11-30
WO2009047565A2 (en) 2009-04-16
CA2701385A1 (en) 2009-04-16
EA201000545A1 (ru) 2010-10-29
MX2010003989A (es) 2010-04-27
SV2010003529A (es) 2010-09-13
HK1143095A1 (en) 2010-12-24
US20120177705A1 (en) 2012-07-12
CL2008003022A1 (es) 2010-07-23
HRP20120085T1 (hr) 2012-02-29
SG182138A1 (en) 2012-07-30
US20090099203A1 (en) 2009-04-16
EP2209501B1 (en) 2011-12-14
AU2008309385B2 (en) 2011-10-20
US8168221B2 (en) 2012-05-01
AU2008309385A1 (en) 2009-04-16
CR11363A (es) 2010-07-14
ES2377426T3 (es) 2012-03-27
EP2209501A2 (en) 2010-07-28
CO6270344A2 (es) 2011-04-20
PT2209501E (pt) 2012-02-03
PL2209501T3 (pl) 2012-03-30
TW200924768A (en) 2009-06-16
NI201000052A (es) 2011-03-24
UY31385A1 (es) 2009-05-29
WO2009047565A3 (en) 2009-11-26
CN101896210A (zh) 2010-11-24
NZ585310A (en) 2012-02-24
JP2011500548A (ja) 2011-01-06
CY1112433T1 (el) 2015-12-09
ATE536893T1 (de) 2011-12-15
BRPI0818323A2 (pt) 2017-05-16
DOP2010000105A (es) 2010-08-15

Similar Documents

Publication Publication Date Title
PE20091032A1 (es) Composicion que contiene n-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridin-3-sulfonamida (zibotentan)
CL2009000394A1 (es) Compuestos derivados de n-(1h-indazol-5-il)pirrolidin-3-carboxamida sustituida, inhibidores de erk; composicion farmaceutica; y su uso en el tratamiento del cancer.
CL2011002706A1 (es) Compuestos derivados de 4-(1,3-oxazol-2-il)-1h-indazol; composicion farmaceutica que los comprende; y sus usos en el tratamiento de enfermedades tales como epoc, autoinmunes, asma, entre otras.
AR112074A2 (es) Derivados de 2-carboxamida-cicloamino-urea como inhibidores de pi-3
PE20141682A1 (es) Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio
PE20211700A1 (es) Compuesto heterociclico y su uso
UY32547A (es) Piperidinas sustituidas como antagonistas de ccr3
UY32884A (es) 1-sustituido-4-(5-(fenil o heteroaril)metoxi)-pirimidin-2-il)piperazinas y piperidinas
CR9214A (es) 2-fenilindoles como antagonistas del receptor de la prostaglandina d2
CR11683A (es) Piridinas y pirazinas como inhibidores de p13k
PE20110298A1 (es) Derivados de picolinamida como inhibidores de cinasa
PE20140105A1 (es) Analogos deuterados de pridopidina utiles como estabilizadores dopaminergicos
ATE482210T1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
PE20141855A1 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
PE20090772A1 (es) Derivados de bencimidazol
CO6541569A2 (es) Inhibidores de n1-pirazoloespirocetona acetil-coa carboxilasa
CL2011001224A1 (es) Compuestos derivados de benzofurano-3-carboxamida; composicion farmaceutica que los comprende; y su uso en tratamiento del virus de la hepatitis c.
CL2009001058A1 (es) Compuestos derivados de oxazinas sustituidas, inhibidores de la 11b-hidroxiesteroide deshidrogenasa de tipo-1; composicion farmaceutica; y uso del compuesto para inhibir la actividad de 11b-hsd1, como en el tratamiento de la diabetes, dislipidemia, hipertension, obesidad, cancer, glaucoma, entre otras.
CL2011001082A1 (es) Compuestos derivados de amino-tetrahidropiranos sustituidos con heterociclos, composicion farmaceutica; y uso en el tratamiento de una afeccion seleccionada de resistencia a la insulina, hiperglicemia y diabetes de tipo 2.
CL2011002115A1 (es) Compuestos derivados de 5-fenil-1h-piridin-2-ona y 5-fenil-pirazin-2-ona, inhibidores de la tirosina-quinasa de bruton (btk); proceso de preparación de los compuestos, compuesto intermediario, composición farmacéutica y uso en el tratamiento de enfermedades inflamatorias y/o autoinmunes.
PE20130340A1 (es) (r)-n-(3-(7-metil-1h-indazol-5-il)-1-(4-metilpiperidin-4-il)piperazin-1-il)-1-oxopropan-2-il)-4-(2-oxo-1,2-dihidroquinolin-3-il)piperidina-1-carboxamida como antagonista del receptor de peptido relacionado con el gen de la calcitonina (cgrp)
EA201071040A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1, cx3cr1 и p40
CL2009000368A1 (es) 3-(amido o sulfamido)-4-(4-azinil sustituido) benzamidas o benzosulfonamidas; la composicion farmaceutica que los contiene; el uso de los compuestos; y un kit que contiene dichos compeustos; utiles como inhibidores del receptor de quimioquinas cxcr3.
PE20142318A1 (es) Formulaciones de (+)-2-[1-(3-etoxi-4-metoxi-fenil)-2-metansulfonil-etil]-4-acetilaminoisoindolin-1,3-diona
GEP20135927B (en) 1-benzyl-3-hydroxymethylindaz-ole derivatives and usage thereat treatment of diseases based on mcp-1, cx3cr1 and p40 expression

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed